围绕天然成分原料搭建风味复配方案平台，「瑞芬生物」获亿元级C轮融资｜36氪首发

Core Insights - Synthetic biology company Ruifen Biotechnology has completed a C-round financing of over 100 million yuan, led by Xingxiang Capital, with funds aimed at commercial expansion and new capacity construction [1] - The company focuses on the sustainable development of natural ingredients, leveraging plant extraction and synthetic biology technologies to create three main product platforms: natural sweeteners, natural functional ingredients, and pharmaceutical excipients [1][2] Company Overview - Ruifen Biotechnology was established in 2007 and is led by founder and CEO Wang Xiaoyun, who has nearly 20 years of experience in the plant extract and natural sweetener industries [1] - The company has formed stable partnerships with leading research institutions, including the Chinese Academy of Sciences and Shanghai Jiao Tong University, to industrialize products like erythritol and allulose [2] Product Development - Allulose, a rare sugar found in fruits, has been recognized as Generally Recognized As Safe (GRAS) by the FDA and has been approved for use as a food additive in China [2] - The company aims to provide comprehensive solutions from raw materials to customized formulations, helping clients quickly capture the health-conscious consumer market [2][3] Market Position and Growth - Ruifen Biotechnology's revenue from innovative compound solutions, centered around functional sugars and natural plant ingredients, is experiencing rapid growth [3] - The company has established three production bases in Shaanxi, Anhui, and Inner Mongolia, with a planned investment of 300 million yuan in the construction of a biosynthesis production base in Hohhot [3] Future Outlook - The company plans to continue strengthening its technological foundation and empower the global food industry by offering healthier, more nutritious, and greener flavor solutions [3]